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The project
• Client: UK National Screening Committee
• Purpose: Help determine IF a national prostate 
cancer screening programme should occur AND 
which screening strategy is best.
• Objectives:
Estimate costs, benefits and resource 
implications of alternative screening options.
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Introduction to prostate cancer
The prostate is a small gland in men behind the 
bladder.
The most common cancer in men in UK
(excluding non-melanoma skin cancer)
In 2008:
Over 37,000 men diagnosed
Over 10,000 men died from prostate cancer
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Aim of screening:
Reduce cancer mortality, morbidity and treatment 
costs through early diagnosis and intervention.
Current evidence:
In 2009 two large RCTs reported apparently 
inconsistent results in terms of the death rate ratio:
• ERSPC – significant reduction in PCa death rate
• PLCO – no statistically significant reduction
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Challenges:
• Effectiveness of different screening programmes 
unknown.
• Scarce data around disease process due to its 
unobservable nature.
• Multiple unknown parameters in cancer 
screening model.
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Solution:
• Develop loosely parameterised cancer 
screening simulation model.
• Calibrate unobservable model parameters to 
observed data.
• Estimate impact of prostate cancer screening 
using calibrated model.
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About the model:
• Disease natural history model (Simul8)
• Calibration module (Excel, Visual Basic)
• Simulation model of prostate cancer screening 
(Simul8)
• Resource impact model (Excel)
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Screening strategies investigated
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• Prostate cancer stage distributions
• Over-detection rate
• Lead time
• Life years gained, QALYs gained
• Probability of developing prostate cancer
• Etc...



























Definitions & terms used
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Disease natural history model
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Data
Data Source
Age specific cancer incidence Office of National Statistics
Cancer stage distributions ProtecT RCT
UK Cancer Registry (ERIC)
Gleason score distributions ProtecT RCT
UK Cancer Registry (ERIC)
PSA/biopsy test characteristics ERSPC RCT (Rotterdam section)
Progression Free Survival ERSPC RCT (Rotterdam section)
Overall Survival ERSPC RCT (Rotterdam section)
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Calibration process
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Total SSE during calibration
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Validation: Incidence
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Validation: PCa mortality
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Validation: BAUS
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Conclusions:
A minimal life gain is offset by the high levels of disease 
management and over-diagnosis:
• One off screening: life gain of 0.004 years (1.2 days) 
with 36 years of additional disease management
• Repeat screening: life gain of 0.03 years (10-11 days) 
with 67-84 years of additional disease management
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Have you heard our findings?
BBC News 06/12/2010 http://www.bbc.co.uk/news/health-11930979
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